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ABSTRACT 
Introduction: During adolescence, exposure to nicotine or cannabis independently induces 
effects on neuromaturation and later cognitive function. However, the potential effect of both 
drugs under co-use conditions has become of increasing concern given the prevalence of e-
cigarettes, legalization of cannabis, and availability of synthetic ‘spice’ cannabinoid agonists. 
Methods: The current studies investigated the effects of  exposure to a cannabinoid receptor 
agonist (WIN55-212,2) and/or nicotine over a discrete time period in mid-adolescence on later 
intravenous nicotine self-administration in adult male and female mice. We further examined 
whether cannabinoid agonist administration in adulthood would alter nicotine reinforcement, 
with either acute or chronic pairing across seven days. Results: We found that adult males 
exhibited increased nicotine self-administration at a lower, rewarding nicotine dose following 
adolescent cannabinoid exposure, either alone or with nicotine co-administration. In contrast, 
adult females demonstrated an opposing effect in which adolescent cannabinoid and nicotine 
co-exposure resulted in decreased nicotine intake compared to the nicotine only and control 
groups. Furthermore, after maintaining nicotine self-administration across sessions, pre-
treatment with a low dose of the cannabinoid agonist decreased nicotine intake in both male and 
female control mice, and this lowering effect was evidenced after both acute and chronic 
treatment. However, the cannabinoid agonist was ineffective in altering nicotine intake in mice 
previously exposed to nicotine, cannabinoid agonist, or both during adolescence. Conclusions: 
These data provide evidence that adolescent drug exposure can alter later nicotine 
reinforcement in a sex-specific manner and can further modulate the effectiveness of 
interventions in reducing nicotine intake during adulthood.         
 IMPLICATIONS: These studies demonstrate a significant impact of nicotine, cannabinoids, or co-
exposure on developmental processes during adolescence. Differential effects were observed 
within each sex, with opposing results found for cannabinoid exposure on nicotine intake in 
males and females. Intriguingly, we also evidenced resistance to the lowering effects of a 
cannabinoid agonist on nicotine intake in adulthood based on adolescent drug exposure. Thus, 
these findings have important implications for our understanding of the impact of nicotine and 
cannabinoids (e.g., THC and synthetic ‘spice’ cannabinoids) during development, with further 
implications for the effectiveness of therapeutic interventions based on prior drug exposure in 
youth. 
  
KEYWORDS: Adolescent, Cannabis, Mouse, Nicotine, Self-Administration  
INTRODUCTION 
Nicotine dependence is among the largest preventable causes of disease and death worldwide. 
Further, polydrug use, including that of nicotine and cannabis, may lead to interactive effects on 
brain neurocircuitries1. Thus, this study represents the first to begin deciphering the co-
consumption effects of nicotine and cannabinoids during adolescent development on later 
dependence and/or resistance to achieving abstinence. According to a 2015 nationwide survey, 
32.3% of high school students self-reported prior cigarette use, whereas 44.9% reported using 
vaporized nicotine products2. Of further concern, 38.6% of these students reported using 
cannabis2. Given that recreational cannabis use was illegal in most states at the time of this 
survey, the number of adolescents exposed to this drug will likely only increase through both 
primary use and second-hand exposure as the drug becomes more readily accessible. This is 
supported by the finding that 44% of 12th graders in a recent 2018 nationwide survey reported 
using cannabis in their lifetime3. Further, the practice of mulling, combining tobacco with 
cannabis to smoke as a joint, has been reported as frequently occurring in adolescent users, with 
highest incidence (up to 90%) among daily cigarette smokers in some populations4,5. 
Furthermore, individuals who reported smoking cannabis and tobacco cigarettes consumed 
more cigarettes than those smoking cigarettes alone6. Together, these findings have introduced 
increasing concerns regarding the interaction between the drugs and the effects of early 
adolescent exposure on later drug taking behaviors. 
 
Nicotine, the main psychoactive component in tobacco and e-cigarettes, acts in the brain on 
neuronal nicotinic acetylcholine receptors (nAChRs), and the psychoactive effects of cannabis 
have been attributed to action on the cannabinoid 1 receptor (CB1R). The CB1Rs are also targeted 
by other abused drug, such as synthetic ‘spice’ cannabinoid agonists for which the majority 
belong to the aminoalkylindole class, including WIN55-212,27-9. The nAChRs and CB1Rs exhibit 
overlapping expression patterns within brain regions implicated in drug reinforcement and 
aversion, including the prefrontal cortex, ventral tegmental area, nucleus accumbens, medial 
habenula, interpeduncular nucleus and hippocampus10,11. On the cellular level, CB1Rs and 
nAChRs are expressed on presynaptic axon terminals, and both function to modulate release of 
neurotransmitters11,12. Reciprocal outcomes are found in their actions and behavioral effects. 
Exogenous cannabinoids can modulate cholinergic neurotransmission in the brain13, and 
similarly, nicotine administration alters endogenous cannabinoid signaling14. Further, similar 
effects are found with neurotransmitter release; for instance, administration of either nicotine 
or the CB1R agonist, WIN55-212,2, increases extracellular dopamine in the nucleus accumbens 
and prefrontal cortex15,16. These findings provide evidence to support the notion that 
exogenously-derived cannabinoid or cholinergic modulation of neurotransmission during 
adolescence may lead to various altered drug-associated behaviors along the continuum of the 
dependence processes.  
 
In humans, tobacco exposure during development has been associated with increased drug use 
during adulthood17,18. However, given the nature of human studies, it is unclear as to whether 
the early life exposure increases vulnerability, or whether a preexisting neural state and/or 
environmental factors prompted consumption of the drug products. In rodents, adolescent 
nicotine exposure results in increased time spent in an environment associated with nicotine 
during adulthood19, suggesting an enhanced rewarding effect of nicotine following prior 
exposure. In an oral self-administration study, rats that drank a nicotine solution during late 
adolescence into early adulthood (PND 35-77) exhibited either a similar level or diminished 
nicotine drinking behavior in later adulthood (PND 140+)20. However, high variability in the 
amount of nicotine consumed has been found in such oral drinking paradigms20, potentially due 
to activation of nAChRs expressed in the tongue and/or post-consummatory gastrointestinal 
effects. In contrast, the intravenous nicotine self-administration procedure is generally accepted 
as having greater translational relevance to human behavior, as stable responding and titration 
of intake are found across doses21,22. A few studies have examined adolescent nicotine exposure 
on later nicotine self-administration in adulthood. In one study in rats, nicotine exposure during 
postnatal days (PND) 25-42 did not alter later nicotine self-administration behavior during early 
adulthood23, but it should be noted that the subjects in this study were individually housed and 
shipped during PND 20-2123; factors that could have elicited stressful conditions during the 
adolescent period. In contrast, another study found a decrease in the motivation to self-
administer nicotine during adulthood; in this paradigm, subjects had variable access to a range 
of nicotine doses for self-administration, including high aversive doses, beginning at PND34 and 
prior to adult testing24, which may have subsequently biased the resultant level pressing 
behavior.  
 
Here, we sought to examine whether adolescent exposure to nicotine and/or a cannabinoid 
agonist would alter intravenous nicotine self-administration during adulthood in male and female 
mice. The current investigations focus on the co-exposure condition, which is commonly found 
in human subjects, and the resulting effects on later nicotine intake. Adolescent mice were 
exposed to a moderate or low dose of the cannabinoid receptor agonist, WIN55,212-2, and/or 
nicotine and then were assessed for nicotine reinforcement behaviors during adulthood. Drug 
exposure occurred during postnatal days 38-49, which corresponds to mid-adolescence in 
rodents or ~13-17 years of age in humans25,26. Given the previously established differential 
responses for males and females with drug-related effects and baseline receptor expression 
across development11,25,27,28, male and female mice were examined in a within-sex manner. 
Finally, we also examined whether acute or repeated administration of the cannabinoid agonist 
during adulthood would alter nicotine self-administration dependent on the prior adolescent 
exposure condition. The goal of this study was to determine if an interaction effect would occur 
during adulthood, in consideration of each adolescent exposure condition. Together, these 
studies provide evidence that adolescent drug exposure alters nicotine reinforcement in a sex-
dependent manner and prevents the dampening effects of a cannabinoid on nicotine intake 
during adulthood in both sexes.  
 
METHODS 
Animals 
Male and female wildtype C57BL/6J mice were derived from breeders in our laboratory animal 
facilities; in total, 54 male and 63 female mice were examined in these studies. Mice were 
maintained in an environmentally controlled vivarium on a 12 h reversed light/dark cycle. Food 
and water were provided ad libitum until behavioral training commenced. During food and 
nicotine self-administration, subjects were mildly food restricted to 85–90% of their free-feeding 
bodyweight, and water was provided ad libitum. All experiments were conducted in strict 
accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved 
by the Institutional Animal Care and Use Committee at the University of California, Irvine.  
 
Drugs 
The cannabinoid receptor agonist WIN55,212-2 mesylate (Tocris/Bio-Techne Corp, Minneapolis, 
ME, USA) was dissolved in vehicle containing 1% DMSO, 1% Tween-80, and 98% saline (sterile 
0.9% NaCl). The doses of WIN55,212-2 administered were 0.2 or 2 mg/kg, intraperitoneally (i.p.). 
The moderate dose of WIN (2 mg/kg) was selected based on prior studies demonstrating altered 
neural function with adolescent exposure in mice and rats29,30, and the low dose of WIN (0.2 
mg/kg) was selected based on evidence from adolescent WIN self-administration in rats (~16 
infusions/day at 0.0125 mg/kg/infusion = ~0.2 mg/kg per day)31. (-)-Nicotine hydrogen tartrate 
salt (MP Biomedicals, Santa Ana, CA, USA; 0215355491) was dissolved in 0.9% sterile saline and 
adjusted to pH 7.4. Nicotine was administered at a dose of 0.36 mg/kg, subcutaneous (s.c.) (free-
base form); this dose is considered to be within the rewarding range of the dose response 
function that also elicits a behavioral response in adolescent C57BL/6J mice28,32,33. Peripheral 
injections were administered at a volume of 10 mL/kg. 
 
Adolescent injection schedule 
Beginning on postnatal day (PND) 38, the first set of male and female mice were randomly 
subdivided into four experimental groups: (1) Control (saline s.c., vehicle i.p.), (2) NIC (0.36 mg/kg 
nicotine s.c., vehicle i.p.), (3) WIN (saline s.c., 2 mg/kg WIN i.p.), and (4) NIC/WIN (0.36 mg/kg 
nicotine s.c., 2 mg/kg WIN i.p.). Saline and vehicle were the solutions used to dissolve nicotine 
and WIN, respectively. Mice received once daily injections for 12 consecutive days from PND 38 
to PND 49. This time frame is considered mid-adolescence in rodents, corresponding to ~13-17 
in human years26. This represents a dynamic developmental period for both the endogenous 
nicotinic acetylcholine and cannabinoid systems; for instance,  the highest level of CB1 receptor 
expression is found during this period11,25,27,28,34. The daily injection schedule was selected to 
model an experimental pattern of adolescent exposure as previously described28. Body weight 
was recorded prior to each injection. The second set of male and female mice were treated as 
above, but they were subdivided into the following experimental groups: 1) Control (saline s.c., 
vehicle i.p.), (2) LdWIN (saline s.c., low dose (0.2 mg/kg) WIN i.p.), and (3) NIC/LdWIN (0.36 mg/kg 
nicotine s.c., 0.2 mg/kg WIN i.p.). All above groups were tested in multiple smaller cohorts to 
enhance rigor and reproducibility of the findings. The current studies were designed to 
systematically assess changes following adolescent exposure under the varying conditions by 
maintaining precise dosing conditions via peripheral injections. 
 
Intravenous nicotine self-administration 
Mice were mildly food restricted to 85-90% of their free-feeding body weight and trained to press 
a lever in an operant chamber (Med Associates, St. Albans, VT) for food pellets (20 mg; TestDiet, 
Richmond, IN) under a fixed-ratio 5, time out 20 sec (FR5TO20 sec) schedule of reinforcement. 
We have previously shown that these adolescent exposure groups do not differ in operant food 
learning28. Once stable responding was achieved (>25 pellets per session across 3 subsequent 
sessions), subjects were surgically catheterized as previously described21,35. Briefly, mice were 
anesthetized with an isoflurane (1-3%)/oxygen vapor mixture and prepared with intravenous 
catheters. Catheters consisted of a 6 cm length of silastic tubing fitted to guide cannula (Plastics 
One, Roanoke, VA) bent at a curved right angle and encased in dental acrylic. The catheter tubing 
was passed subcutaneously from the animal’s back to the right jugular vein, and a 1 cm length of 
the catheter tip was inserted into the vein and tied with surgical silk suture. Following the surgical 
procedure, animals were allowed ≥48 h to recover from surgery, then provided access to again 
respond for food reward. Mice were then permitted to acquire intravenous nicotine self-
administration during 1 h daily sessions, 6-7 days per week, at the standard training dose of 
nicotine (0.03 mg/kg/infusion). Nicotine was delivered through tubing into the intravenous 
catheter by a Razel syringe pump (Med Associates). Each session was performed using 2 
retractable levers (1 active, 1 inactive). Completion of the response criteria on the active lever 
resulted in the delivery of an intravenous nicotine infusion (0.03 ml infusion volume; FR5TO20 
sec schedule). Responses on the inactive lever were recorded but had no scheduled 
consequences. Catheters were flushed daily with physiological sterile saline solution (0.9% w/v) 
containing heparin (10 USP units). Catheter integrity was tested with the short-acting barbiturate 
anesthetic Brevital (methohexital sodium, Eli Lilly, Indianapolis, IN). Subjects and their data were 
removed from the study due to death or if the catheter integrity was compromised as determined 
by visual leakage or Brevital assessment. Behavioral responses were automatically recorded by 
MedAssociates software.  
 
Experimental Design 
The experimental design is outlined in Figure 1. Following adolescent injections, mice remained 
drug-free until adulthood (PND70). Thereafter, they were examined for differences in cognitive 
behavior as reported previously28. For these investigations, to ascertain the dose response 
function, mice were tested according to the established mouse intravenous self-administration 
protocol21. Following an acquisition period of at least 7 days on the training dose (0.03 
mg/kg/infusion), the animals were presented with a different dose of nicotine for at least 5 days, 
and the mean intake for the last 2 sessions was used for statistical analyses. In between each 
dose, subjects were returned to the 0.1 mg/kg/infusion dose for 2 days or until intake returned 
to baseline levels. The dose response function occurred over a total ~35 sessions with testing 
sessions occurring 6 days per week. Thereafter, mice were stabilized on the moderate 0.1 
mg/kg/infusion dose across three baseline sessions after successfully passing the Brevital 
catheter patency test. Then, subjects were challenged with an injection of the low dose WIN (0.2 
mg/kg) or vehicle control, 20 min prior to the nicotine self-administration session. Injections of 
vehicle or low dose WIN were administered in a random, counterbalanced design both within 
and across groups, and subjects were permitted at least 2 baseline days in between WIN/vehicle 
administration to return to baseline levels of nicotine intake. After the cross-over experiment 
with the single, acute dose of WIN, mice were chronically pre-treated with the same low WIN 
dose prior to each session across 7 consecutive sessions, and nicotine intake on the seventh 
session was used to determine the effects of chronic co-exposure during adulthood for all groups. 
Since the control groups (adolescent vehicle treatment) for the moderate and low dose WIN 
cohorts exhibited similar effects with pre-treatment, data were compiled into one graph for each 
sex. Finally, mice were again returned to self-administer the 0.1 mg/kg/infusion dose, and after 
achieving baseline levels of responding, they were then transitioned to respond for saline 
infusions (no nicotine). Eleven mice were required to be excluded due to death/cannibalization 
by cagemates (3 female Control, 1 female NIC, 3 female and 1 male NIC/WIN, 2 female 
NIC/LdWIN, and 1 male LdWIN), and 6 were excluded due to compromised catheter integrity (2 
female Control, 2 female NIC, 1 female NIC/LdWIN, 1 male LdWIN). 
 
Statistical analyses 
Given that these studies sought to investigate the effects of drug exposure relative to the control 
condition within each sex, statistical comparisons were performed separately for males and 
females based on this a priori hypothesis28. Data were analyzed by a t-test, one-way or two-way 
ANOVA with Prism 7 software (GraphPad, La Jolla, CA, USA), as appropriate. Data obtained across 
sessions were analyzed with a repeated measures two-way ANOVA. Significant main or 
interaction effects were followed by Bonferroni post-hoc comparison with correction for multiple 
comparisons. The criterion for significance was set at α=0.05. 
 
RESULTS 
Intravenous Nicotine Self-Administration During Adulthood 
Adolescent exposure groups were examined for differences in nicotine intake during adulthood 
across low, moderate, and high self-administration doses (Figure 1a). This approach allows for 
the assessment of the dose response function, which provides a measure of responding across 
nicotine doses with increasing value of reinforcement (ascending limb of the dose response) and 
doses inducing greater aversion and/or satiation (descending limb of the dose response) 21. In 
male mice, significant differences were found on the ascending limb at the 0.03 mg/kg/infusion 
dose, but not at higher doses (Figure 2a) (Repeated measures two-way ANOVA, Group 
F(3,25)=2.13, p=0.122; Dose F(3,75)=38.15, p<0.0001; Interaction F(9,75)=2.29, p=0.024). Specifically, 
the WIN and nicotine/WIN adolescent exposure groups exhibited a significantly increased 
number of nicotine infusions compared to the control and nicotine adolescent exposure groups 
(p<0.05 for WIN compared to either control or nicotine; p<0.01 for nicotine/WIN compared to 
either control or nicotine). Further, the groups did not differ in their saline level of responding, 
indicating that these differences were not due to a general increase in lever pressing behavior. 
Since both the WIN and nicotine/WIN exposure conditions involved a moderate dose of the 
cannabinoid agonist (2 mg/kg), we next addressed the possibility that this WIN dose could have 
masked the effects of nicotine in an interactive effect. Thus, we examined a separate cohort of 
mice exposed to a low dose of WIN (0.2 mg/kg), either in the presence or absence of nicotine. 
However, differences were not found in the dose response function among these adolescent 
treatment conditions, with all groups exhibiting a main effect for nicotine dose (Figure 2b) 
(Repeated measures two-way ANOVA, Group F(2,19)=1.06, p=0.368; Dose F(3,57)=15.51, p<0.0001; 
Interaction F(6,57)=0.845, p=0.541). 
 
In female mice, statistically significant main and interaction effects were found among the 
control, nicotine, WIN, and co-exposure nicotine and WIN groups (Figure 2c) (Repeated measures 
two-way ANOVA, Group F(3,24)=5.24, p=0.006; Dose F(3,72)=33.44, p<0.0001; Interaction 
F(9,72)=2.82, p=0.007). The post-hoc analysis revealed an upward shift in the dose response 
function for the nicotine exposure group, as compared to both the WIN and co-exposure nicotine 
and WIN groups. Specifically, at the 0.03 mg/kg/infusion dose, the adolescent nicotine group 
exhibited a significantly greater number of nicotine infusions than the adolescent WIN (p<0.001) 
and nicotine/WIN co-exposure (p<0.01) groups. At the moderate 0.1 mg/kg/infusion dose, the 
nicotine group also demonstrated a statistically significant increase from the WIN group (p<0.01) 
and nicotine/WIN co-exposure group (p<0.001), and the nicotine/WIN co-exposure group was 
also significantly decreased compared to the control group (p<0.05). No other groups 
significantly differed from the control, or at the saline and high dose of nicotine (0.4 
mg/kg/infusion). Thereafter, a second set of female mice were examined for differences with the 
lower dose of WIN. However, the low dose WIN adolescent exposure groups, either in the 
presence or absence of nicotine, did not differ across the dose response function from the control 
condition, with a significant main effect of dose evidenced (Figure 2d) (Repeated measures two-
way ANOVA, Group F(2,18)=0.42, p=0.662; Dose F(3,54)=29.26, p<0.0001; Interaction F(6,54)=0.45, 
p=0.842).  
 
Interactive Effects of Acute or Chronic WIN Exposure During Adult Nicotine Self-Administration 
To examine whether further exposure in adulthood to a cannabinoid agonist subsequently alters 
nicotine intake, mice were pretreated with the low dose of the cannabinoid agonist or vehicle 
prior to a nicotine self-administration session; thereafter, the mice were then repeatedly 
administered the low dose of the cannabinoid agonist prior to seven consecutive nicotine self-
administration sessions (Figure 1b). In adult males, we found that both acute and chronic 
treatment with WIN significantly attenuated nicotine intake relative to the vehicle control 
(Repeated measures one-way ANOVA, F(2,32)=8.09, p=0.001; Post-hoc, vehicle vs. acute p<0.05, 
vehicle vs. chronic p<0.01) (Figure 3a), indicating that cannabinoid co-use in adulthood reduces 
nicotine consumption. Interestingly, when we examined the adolescent exposed nicotine and 
WIN groups, a stark contrast in responding was evidenced. Across all adolescent drug groups, the 
cannabinoid agonist was ineffective in altering nicotine intake relative to infusions earned 
following vehicle injection (Repeated measures one-way ANOVAs: Nicotine, F(2,14)=0.37, p=0.695; 
WIN, F(2,16)=0.61, p=0.554; Low dose WIN, F(2,12)=5.77, p=0.018; Nicotine and WIN co-exposure, 
F(2,8)=1.75, p=0.234; Nicotine and low dose WIN co-exposure, F(2,14)=2.67, p=0.104) (Figures 3b, 
3c, 3d, 3e, 3f, respectively).  
 
In adult females, the control group exhibited a similar effect of cannabinoid agonist pretreatment 
in reducing nicotine intake as to that found in the males (Repeated measures one-way ANOVA, 
F(2,26)=15.94, p<0.0001) (Figure 4a). Specifically, in post-hoc analyses, the vehicle condition 
exhibited a higher level of nicotine infusions compared to pretreatment with the cannabinoid 
after one session (acute, p<0.05) and after seven consecutive sessions (chronic, p<0.0001). 
Further, chronic administration of the cannabinoid agonist induced significantly reduced nicotine 
intake to a greater extent than the acute condition (p<0.05). However, adolescent drug exposure 
resulted in a resilience to the effects of the cannabinoid agonist during adulthood on nicotine 
intake, since differences were not found in the number of nicotine infusions earned after 
cannabinoid agonist injection for all other groups (Repeated measures one-way ANOVAs: 
Nicotine, F(2,12)=3.09, p=0.083; WIN, F(2,16)=2.16, p=0.148; low dose WIN, F(2,14)=2.11, p=0.158; 
Nicotine and WIN co-exposure, F(2,10)=2.11, p=0.173; Nicotine and low dose WIN co-exposure, 
F(2,10)=0.27, p=0.771) (Figures 4b, 4c, 4d, 4e, 4f, respectively).   
 DISCUSSION 
In these studies, we found that adolescent cannabinoid and/or nicotine exposure exert a lasting 
impact on susceptibility to drug reinforcement, which is evidenced in adulthood. However, these 
effects were dependent on the substance of abuse (cannabinoid agonist or nicotine), dose of the 
cannabinoid, and sex. Specifically, adult males exhibited increased nicotine self-administration at 
the lower rewarding nicotine dose following adolescent cannabinoid agonist exposure at the 
moderate dose (2 mg/kg), either alone or with nicotine co-administration. In contrast, adult 
females demonstrated an opposing effect following adolescent cannabinoid exposure at the 
moderate dose, in which such exposure resulted in decreased nicotine intake compared to 
nicotine exposure alone. However, differences were not induced within either sex with 
adolescent exposure to the lower dose of the cannabinoid agonist (0.2 mg/kg).  Furthermore, 
after maintaining nicotine self-administration, pre-treatment with the low dose of the 
cannabinoid agonist attenuated nicotine intake in both male and female control mice, and this 
lowering effect was evidenced both acutely and after chronic pairings. Surprisingly, the 
cannabinoid agonist was ineffective in altering nicotine intake in mice previously exposed to 
nicotine, the cannabinoid agonist, or both during adolescence; an effect that was present at both 
the lower and moderate doses of the cannabinoid agonist.   
 
Impact of adolescent drug exposure on adult nicotine intake  
Nicotine self-administration produces an inverted U-shaped dose-response curve, which 
represents the competing positive and negative properties of nicotine. The increased responding 
for nicotine over the ascending limb of the curve reflects the increasing reinforcing effects of 
nicotine as the unit dose increases. In contrast, the decreased responding over the descending 
limb of the curve reflects the increasing aversive properties of nicotine or satiation. Mesolimbic 
dopamine neurons have been primarily implicated in modulating the rewarding and reinforcing 
aspects of the drug 36, whereas the aversive signaling of nicotine appears to involve the habenulo-
interpeduncular pathway 12. Our findings suggest that adolescent cannabinoid exposure most 
likely alters the function of the mesolimbic pathway, as differences were found primarily on the 
ascending limb of the dose response function. In support of this notion, adolescent cannabinoid 
or nicotine exposure has previously been shown to alter monoaminergic signaling 37-40. However, 
in our study, nicotine alone was ineffective in altering later drug taking behaviors in males, either 
in combination with the cannabinoid or alone. Since studies have shown that of those 
adolescents age 12-17 who smoke, the majority smoke one or less than one cigarette per day 
(50.1%) 41, the current studies focused on a rewarding dose with once daily exposure of a 
rewarding dose 28,32,33.  Thus, the current results have particular relevance to experimental 
patterns of drug consumption found in youth.  
 
Differential patterns of expression of the cannabinoid receptors are found across adolescent 
development and between males and females 42, and cannabinoid 1 receptors (CB1Rs) exhibit 
highest level of expression during the developmental period of mid-adolescence (PND 25-50) 42. 
Thus, the potential for exogenous cannabinoids to alter synaptic and neural circuit function may 
be considered greatest during this time period. Indeed, prior studies have revealed an effect of 
CB1R activation on adolescent brain development and indicate a correlation between adolescent 
exposure and later cognition and reward-related function. For instance, we found that adult 
males exposed during adolescence to the moderate 2 mg/kg dose of WIN exhibited increased 
cognitive flexibility in a learning reversal task, decreased anxiety-associated behaviors, and 
increased natural reward consumption with the same exposure paradigm 28. The co-exposure 
condition of both nicotine and the moderate dose of WIN also led to similar behavioral profiles 
as WIN alone in these measures 28, suggesting that a potentiative or additive effect was not 
present similar to that found in the current studies with nicotine intake.  With regard to females, 
they were found to be overall more resistant to the long-term effects of adolescent drug 
exposure, in which the moderate dose WIN females exhibited decreased natural reward 
consumption compared to the control females28. Interestingly, CB1R knockout mice are resistant 
to nicotine-mediated locomotion and CPP, but do not differ in nicotine self-administration, as 
compared to wildtype mice43,44, which suggests that the lack of CB1Rs during adulthood may 
affect generalized locomotor behavior and drug-conditioned memory function, but perhaps not 
the motivation to consume nicotine. However, given the constitutive knockout of the gene in 
these mice, it is possible that compensatory mechanisms occurred during development, resulting 
in altered expression of other receptors, potentially including cannabinoid 2 receptors and/or 
nAChRs.  
 
Adolescent exposure infers resistance to a cannabinoid-induced decrease in nicotine intake 
Both single and co-use of nicotine and cannabinoid products are prevalent during adolescence 
and adulthood. Thus, we further examined co-exposure during adulthood, under both control 
conditions and following adolescent drug exposure.  In the control group, we found that the low 
dose of the cannabinoid agonist reduced nicotine intake in adulthood. This represents the first 
demonstration of the effects of a cannabinoid agonist on intravenous nicotine self-administration 
in mice. These results were surprising since the CB1 receptor antagonists rimonabant and 
taranabant have also been shown to reduce nicotine consumption45. However, when one 
considers that additive effects may be induced on brain reward circuitries, such as that found 
with reduced brain stimulation thresholds in the presence of rewarding doses of nicotine, it is 
likely that the presence of the cannabinoid agonist augmented the activity of the reward circuits 
in the brain, leading to a reduction in nicotine intake while maintaining similar circuit activation 
to support drug reinforcement. However, this stipulation will need to be more directly tested in 
future studies. 
 
We further found that the effectiveness of the cannabinoid agonist in reducing nicotine self-
administration is dependent on prior drug exposure during adolescence, as all of the adolescent 
nicotine and/or WIN exposure groups did not differ in nicotine intake with WIN pretreatment in 
adulthood. Of further note, we found that this lack of responsiveness to the dampening effects 
of the cannabinoid agonist on nicotine intake also occurred in adolescent groups exposed to the 
low dose of the cannabinoid agonist. It is important to note that this level of exposure did not 
induce any other detectable behavioral effects during adulthood, either in this study or in our 
prior analysis of cognitive, anxiety- and depression-associated behaviors28. Given these findings, 
it is possible that patients may differentially respond to pharmacotherapeutics based on 
developmental drug exposure, representing a potential underlying factor mitigating individual 
differences in cessation outcomes. Indeed, given that we found differences in nicotine intake 
during adulthood with developmental drug exposure, and currently available 
pharmacotherapeutics such as varenicline also target nAChRs, similar signaling mechanisms may 
be involved in mitigating the behavioral responses to these drug compounds. 
 
Finally, in these studies, we examined the effects of an injected cannabinoid agonist during 
adolescent development on nicotine self-administration in adulthood. Importantly, these results 
have direct implications for the use of ‘spice’ synthetic cannabinoids, of which the majority 
belong to the aminoalkylindole (AAI) class, including WIN 55,212-27-9.  In addition, these findings 
likely have further implications for cannabis exposure. THC has been characterized as a partial 
agonist of the CB1R, and therefore, it is possible that the low dose of the WIN agonist could have 
resulted in the occupation of a fewer number of receptors, thereby inducing an effect more 
similar to a higher dose of a partial agonist on downstream cellular signaling. However, this will 
need to be more systematically addressed in future studies. Moreover, while it is possible that 
volitional intake during adolescence may differentially alter drug reinforcement, rather than 
experimenter administered injections, there are some caveats to such an experimental design. 
First, it is not yet feasible to implant intravenous catheters in adolescent mice. Second, the dose 
that each animal receives cannot be discretely controlled with self-administration studies. This 
point is further compounded by the fact that co-exposure conditions result in different intake 
amounts of each drug, as compared to single use conditions. Furthermore, both THC and WIN 
self-administration in rodent models have been difficult to establish in many labs, although some 
have been successful due to specific doses and reinforcement testing paradigms31,46,47. In 
particular, for THC in rats, the combined presence of CBD appears to be necessary to enhance 
the development of sustained self-administration behavior in both intravenous and vapor 
paradigms47,48. This is interesting given that some THC e-cigarette vapes on the market do not 
necessarily contain CBD, at least as indicated on commercial packaging. Given these 
considerations and with the foundational findings derived from the current studies, it will 
nevertheless be important in future studies to develop models for volitional adolescent nicotine 
and cannabinoid self-administration, perhaps via vapor exposure, and then to determine 
whether the variable, self-titrated levels of each drug differentially impacts nicotine and/or 
cannabinoid self-administration in adulthood.  
 
CONCLUSIONS 
In these studies, we have found that adolescent cannabinoid and/or nicotine exposure leads to 
differential effects on nicotine-taking behaviors in male and female mice. Further, such 
developmental exposure appears to alter the brain’s later responsiveness with important 
implications for co-use conditions, in which developmental cannabinoid or nicotine exposure 
leads to sustained use of nicotine with cannabinoid co-exposure in adulthood. In future studies, 
it will be important to examine both self-administered nicotine and cannabinoid exposure during 
adolescence and throughout the transition from adolescence to adulthood, as well as adolescent 
nicotine and cannabinoid exposure on other aspects of nicotine dependence, including 
withdrawal and relapse-related reinstatement behaviors. It will also be important to assess 
whether the impact of adolescent exposure differs due to genetic factors mitigating vulnerability. 
For instance, it has been demonstrated that humans with allelic variation in the catechol-O-
methyltransferase gene are more likely to develop schizophrenia-related symptomology 
following adolescent cannabinoid use49, a finding that is of further relevance given the very high 
comorbidity found between schizophrenia and nicotine dependence50. In sum, given the 
increased adolescent use of nicotine and THC containing e-cigarettes, along with the availability 
of cannabis and synthetic ‘spice’ products, the long-term consequences of developmental drug 
exposure represent an important health issue, and as such, the current findings should serve to 
guide future policy efforts to limit youth exposure.  
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Figure Legends 
Figure 1. Schematic outline of the experimental design. (a) All mice were treated in adolescence 
with nicotine (NIC), WIN55,212-2 (WIN), NIC/WIN co-exposure, or vehicle control. WIN was 
administered at either a low or high dose for the single and co-exposure conditions. After PND70, 
mice began testing for subsequent examination of intravenous nicotine self-administration 
across doses. (b) After reestablishing baseline responding on the 0.1 mg/kg/infusion nicotine 
dose, mice were then pre-treated across sessions with vehicle or low dose WIN in a cross-over 
design. Thereafter, mice were examined with chronic low dose WIN and nicotine self-
administration co-exposure for 7 consecutive testing sessions. Finally, after again re-establishing 
baseline responding, mice were transitioned to respond for saline infusions in the absence of 
nicotine.  
 
Figure 2. Male and female mice exposed to the cannabinoid agonist during adolescence exhibit 
opposing effects on nicotine self-administration in adulthood. (a-b) Male intravenous nicotine 
self-administration dose response function. (a) Following exposure to the cannabinoid agonist 
WIN during adolescence, adult male mice demonstrated an increase in nicotine intake on the 
ascending limb of the dose response function at the 0.03 mg/kg/infusion dose compared to the 
vehicle control and nicotine only (NIC) groups. A similar increase in nicotine intake was also found 
with nicotine and WIN co-exposure (NIC/WIN) at this dose compared to both the vehicle and NIC 
groups. (n=6-8/group) *p<0.05 Control vs. WIN, and NIC vs. WIN; **p<0.01 Control vs. NIC/WIN, 
and NIC vs. NIC/WIN. (b) Adult male mice administered the lower dose of WIN (0.2 mg/kg), either 
in the presence or absence of nicotine, during adolescence did not exhibit statistically significant 
differences from the control across the dose response function (n=7-8/group). Data represent 
mean values ± SEM. (c-d) Female intravenous nicotine self-administration dose response 
function. (c) Adult female mice exposed to nicotine (NIC) during adolescence earned significantly 
more nicotine infusions at the low (0.03 mg/kg/infusion) and moderate (0.1 mg/kg/infusion) 
doses, as compared to the adolescent-exposed cannabinoid agonist WIN groups, either alone or 
with nicotine co-exposure. The co-exposure WIN and nicotine group also earned significantly less 
nicotine infusions than the control condition at the moderate 0.1 mg/kg/infusion dose. (n=6-
9/group) #p<0.01 NIC vs. WIN or NIC/WIN; *p<0.05 Control vs. NIC/WIN. (d) Adult female mice 
administered the low dose of WIN during adolescence, alone or with nicotine, did not differ from 
the control vehicle group across the dose response function (n=6-8/group). 
  
Figure 3. Adolescent drug exposure in male mice results in resistance to the effects of the 
cannabinoid agonist on nicotine intake in adulthood. (a) Control male mice exhibit a statistically 
significant reduction in nicotine intake after acute cannabinoid agonist pre-administration and 
following seven consecutive days of treatment (chronic) in adulthood (n=17) *p<0.05, **p<0.01 
compared to vehicle injection. (b-f) Administration of a low dose of the cannabinoid agonist 
during adulthood was ineffective in altering nicotine intake in male mice exposed to the following 
during adolescence: (b) nicotine (n=8), (c) the cannabinoid agonist WIN (n=9), (d) low dose of the 
cannabinoid agonist WIN (n=7), (e) co-exposure of nicotine and the cannabinoid agonist WIN 
(n=5), or (f) co-exposure of nicotine and the low dose of the cannabinoid agonist WIN (n=8).  
 
Figure 4. Adolescent nicotine or cannabinoid agonist exposure in female mice prevents the 
lowering effect of the cannabinoid agonist on nicotine intake in adulthood. (a) Control female 
mice earned significantly fewer nicotine infusions both after an acute cannabinoid agonist pre-
administration and with chronic exposure (n=14). *p<0.05 for vehicle vs acute WIN, and acute 
WIN vs chronic WIN, ****p<0.0001 for vehicle vs chronic WIN. (b-f) The cannabinoid agonist was 
ineffective in altering nicotine intake during adulthood in female mice with adolescent exposure 
to: (b) nicotine (n=7), (c) the cannabinoid agonist WIN (n=9), (d) low dose of the cannabinoid 
agonist WIN (n=8), (e) co-exposure of nicotine and the cannabinoid agonist WIN (n=6), or (f) co-
exposure of nicotine and the low dose of the cannabinoid agonist WIN (n=6).  
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